Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2019 / Aug / Gaining the Upper Hand
Clinical Mass Spectrometry Pharma and Biopharma

Gaining the Upper Hand

Measuring antiretroviral drug accumulation in the brain with MALDI-MSI to inform the best therapeutic avenue for HIV-associated neurocognitive disorder

By Jonathan James 08/13/2019 1 min read

Share

Thanks to recent advances in antiretroviral (ARV) therapy, the life expectancy of HIV patients is now almost equal to that of the general population – at least in more developed nations. But, as life expectancy continues to increase, long term HIV-associated complications, such as HIV-associated neurocognitive disorder (HAND), represent a growing health concern (1). The pathology of HAND is underscored by an accumulation of HIV particles in the central nervous system; over time, the disorder prevents sufferers from carrying out basic tasks and eventually results in death. But which ARV drugs are likely to be most effective?

Thanks to recent advances in antiretroviral (ARV) therapy, the life expectancy of HIV patients is now almost equal to that of the general population – at least in more developed nations. But, as life expectancy continues to increase, long term HIV-associated complications, such as HIV-associated neurocognitive disorder (HAND), represent a growing health concern (1). The pathology of HAND is underscored by an accumulation of HIV particles in the central nervous system; over time, the disorder prevents sufferers from carrying out basic tasks and eventually results in death. But which ARV drugs are likely to be most effective?

Sooraj Baijanth and colleagues at the University of KwaZulu-Natal in Durban, South Africa, used LC-MS/MS and matrix-assisted laser desorption/ionization MS imaging (MALDI-MSI) to study the spatial distribution of two ARV drugs, elvitegravir and tenofovir, in rat brains (2). The researchers found that elvitegravir demonstrated around 20 times higher blood-brain barrier penetration than tenofovir, reaching a maximum concentration of 976 ng/g. 

According to Baijanth, the approach developed by the researchers provides higher spatial resolution than other modalities and should allow them to map numerous analytes in tissue sections. Such capability will prove useful as they complete an evaluation of all FDA-approved ARV drugs before assigning them to a “brain penetration index.” The team hopes that the index will eventually help clinicians select the most appropriate treatment regimen for patients presenting with HAND symptoms.

Progress that cannot come soon enough, Baijanth remarks, reflecting on the “constraints and dangers associated with exposure to radioactivity” associated with PET imaging - the technique historically associated with tissue imaging studies. Baijanth is confident that improvements in the speed, accuracy and resolution of MALDI-MSI will continue as MS-based imaging becomes increasingly popular: “Such advances are sure to enhance the ability of researchers to conduct imaging experiments in situ, and will subsequently encourage translation into the clinic.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. D Saylor et al., “HIV-associated neurocognitive disorder – pathogenesis and prospects for treatment”, Nat Rev Neurol, 12, 234-248 (2016). DOI: 10.1038/nrneurol.2016.27
  2. S Ntshangase et al., “Spatial distribution of elvitegravir and tenofovir in rat brain tissue: Application of MALDI-MSI and LC-MS/MS", Rapid Commun Mass Spectrom [Epub head of print](2019). DOI: 10.1002/rcm.8510

About the Author(s)

Jonathan James

Having thrown myself into various science communication activities whilst studying science at University, I soon came to realize where my passions truly lie; outside the laboratory, telling the stories of the remarkable men and women conducting groundbreaking research. Now, at Texere, I have the opportunity to do just that.

More Articles by Jonathan James

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.